Interesting data from a Phase 3 trial on Hereditary Angioedema, a condition causing severe swelling. A single CRISPR gene editing infusion reduced attacks by 87%. 62% of 80 treated patients became attack-free. Looks promising for a long-term solution.
A groundbreaking Phase 3 clinical trial has shown that a single intravenous infusion of lonvoguran ziclumeran, an in vivo CRISPR-Cas9 gene editing therapy, significantly reduced attacks in patients wi
